(Q29998867)

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

Adaptive radiation therapy

20 May 2017

main subject

0 references

1 reference

1 reference

1 reference

Riad Salem

1

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

20 May 2017

Kenneth G. Thurston

2

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

20 May 2017

Brian I. Carr

3

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

20 May 2017

James E. Goin

4

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

20 May 2017

Jean-Francois H. Geschwind

5

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

20 May 2017

publication date

September 2002

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

Journal of Vascular and Interventional Radiology

20 May 2017

published in

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

20 May 2017

volume

13

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

20 May 2017

issue

9

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

20 May 2017

page(s)

S223-S229

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

20 May 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 patients in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Hepatocellular carcinoma in Central Europe: prognostic features and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Hepatic malignancies: improved treatment with intraarterial Y-90

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

Determinants of postembolization syndrome after hepatic chemoembolization

1 reference

https://api.crossref.org/works/10.1016%2FS1051-0443%2807%2961790-4

7 January 2021

10.1016/S1051-0443(07)61790-4

Identifiers

DOI

1 reference

https://doi.org/10.1016%2FS1051-0443%2807%2961790-4